Current Report Filing (8-k)
December 14 2016 - 10:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported)
|
December 13,
2016
|
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
333-143570
|
36-4296006
|
(Commission File
Number)
|
(IRS
Employer Identification No.)
|
4203 SW 34
th
St.
|
|
Orlando, FL
|
32811
|
(Address of
Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 7.01
Regulation FD Disclosure.
The
investor presentation included as Exhibit 99.1 to this report may
be presented at meetings with investors, analysts, and others, in
whole or in part and possibly with modifications, during the fiscal
year ending December 31, 2016 and December 31, 2017.
By
filing this Current Report on Form 8-K and furnishing the
information contained herein, the Company makes no admission as to
the materiality of any information in this report that is required
to be disclosed solely by reason of Regulation FD. The information
contained in the investor presentation is summary information that
is intended to be considered in the context of the Company's
Securities and Exchange Commission (“SEC”) filings and
other public announcements that the Company may make, by press
release or otherwise, from time to time. The Company undertakes no
duty or obligation to publicly update or revise the information
contained in this report, although it may do so from time to time
as its management believes is warranted. Any such updating may be
made through the filing of other reports or documents with the SEC,
through press releases or through other public
disclosure.
The
information presented in Item 7.01 of this Current Report on Form
8-K and Exhibit 99.1 shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, unless the Company specifically
states that the information is to be considered “filed”
under the Exchange Act or specifically incorporates it by reference
into a filing under the Securities Act of 1933, as amended, or the
Exchange Act.
Item 9.01 Financial
Statements and Exhibits
.
Exhibit Description
99.1
Investor Presentation
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
Date:
December 14, 2016
|
By:
|
/s/ David Patterson
|
|
|
David
Patterson
|
|
|
Chief
Executive Officer
|
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Apr 2024 to May 2024
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From May 2023 to May 2024